Physician profile
Roger E Sharf
NPI 1275621286
$2,663.35
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,174 · 2020: $466 · 2022: $23.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $688.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $283.08 | 2019-2020 | |
| Amgen INC. | $267.74 | 2019-2020 | |
| Pfizer INC. | $256.27 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $225.47 | 2019-2020 | |
| Lilly USA, LLC | $177.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.66 | 2019-2020 | |
| Novo Nordisk INC | $158.51 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $86.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $55.60 | 2019 | |
| Abbott Laboratories | $47.92 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $43.47 | 2019 | |
| Horizon Therapeutics Plc | $36.86 | 2019-2020 | |
| Bioventus LLC | $28.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $23.70 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2019 | |
| Allergan, INC. | $19.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.27 | 2019 | |
| Astellas Pharma US INC | $18.53 | 2019 | |
| Merck Sharp & Dohme LLC | $11.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Sharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.